Laureline Wetterwald

Dr. Laureline Wetterwald

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
LWLaureline Wetterwald
Laureline Wetterwald
NRNicolò Riggi
Nicolò Riggi
AKAnastasios Kyriazoglou
Anastasios Kyriazoglou
GTGiovanni Dei Tos
Giovanni Dei Tos
ATAngelo Dei Tos
Angelo Dei Tos
ADAntonia Digklia
Antonia Digklia
Clear cell sarcoma (CCS) is an ultra-rare soft tissue sarcoma (STS) with a poor prognosis due to propensity to metastasize and its low chemosensitivity. The standard treatment of localized CCS cons...

31 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LWLaureline Wetterwald
Laureline Wetterwald
ASAPOSTOLOS SARIVALASIS
APOSTOLOS SARIVALASIS
ALAikaterini Liapi
Aikaterini Liapi
PMPatrice Mathevet
Patrice Mathevet
CAChahin Achtari
Chahin Achtari
Borderline ovarian tumors (BOTs) account for 10–20% of epithelial ovarian neoplasms. They are characterized by their lack of destructive stromal invasion. In comparison to invasive ovarian cancers, BOTs occur in younger patients and have better outcome. Serous borderline ovarian tumor (SBOT) represents the most common subtype of BOT. Complete surgical staging is the current standard management but fertility-sparing surgery is an option for SBOT patients who are at reproductive age. While most cases of SBOTs have an indolent course with favorable prognosis, late recurrence and malignant transformation can occur, usually in the form of low-grade serous carcinoma (LGSC). Thus, assessment of the recurrence risk is essential for the management of those patients. SBOTs can be associated with lymph node involvement (LNI) in up to 30% of patients who undergo lymph node dissection at diagnosis, and whether LNI affects prognosis is controversial. The present review suggests that recurrent SBOTs with LNI have poorer oncological outcomes and highlights the biases due to the scarcity of reports in the literature. Preventing SBOTs from recurring and becoming invasive overtime and a more profound understanding of the underlying mechanisms at play are necessary.

1 October 2024 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
LWLaureline Wetterwald
Laureline Wetterwald
SPSotirios Papadopoulos
Sotirios Papadopoulos
GTGeorgia Tsoumakidou
Georgia Tsoumakidou
SBSarah Boughdad
Sarah Boughdad
DFDaniela Ferraro
Daniela Ferraro
ADAntonia Digklia
Antonia Digklia
Background: Metastatic dedifferentiated liposarcoma (DDLPS) is primarily managed with chemotherapy, yet with poor response rate. Locoregional therapies, such as radiotherapy and percutaneous cryoablation, can provide palliation for inoperable metastatic sarcomas. In rare instances, those ablative therapies can elicit an immune-mediated regression of untreated metastases in a process named the abscopal effect. With the growing use of immunotherapy, reports on the abscopal effect have become more frequent during the last decade. Case Description: A 55-year-old patient with no prior medical history was diagnosed with a stage IV DDLPS. The patient was first treated with induction chemotherapy followed by en bloc resection and adjuvant radiotherapy. After two local relapses treated with chemotherapy, the patient developed a systemic disease progression. While progressing on immunochemotherapy, the patient underwent palliative percutaneous cryoablation. Three months after the procedure, the 18fluorodeoxyglucose positron emission tomography/computed tomography (18FDG PET/CT) showed regression of the distant metastasis alongside the regression of the cryoablated tumor, suggesting an abscopal effect. Conclusions: The occurrence of the abscopal effect after progressive disease suggests that cryoablation triggered a systemic immune response, highlighting the potential of this treatment combination. However, it remains a rare phenomenon, and further research and clinical trials are required to determine optimal treatment sequencing.

1 December 2023 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
ASAntonia Stamatiou
Antonia Stamatiou
TNTu Nguyen-Ngoc
Tu Nguyen-Ngoc
LWLaureline Wetterwald
Laureline Wetterwald
ADAna Dolcan
Ana Dolcan
GTGiovanni Dei Tos
Giovanni Dei Tos
ADAntonia Digklia
Antonia Digklia
Tenosynovial giant cell tumor (TGCT) is a rare and locally aggressive benign tumor arising from the synovium of joints, bursae, and tendon sheaths. It is classified into localized (L-TGCT) and diffuse (D-TGCT) forms based on the extent of involvement. Surgical resection is the primary treatment, though achieving a definitive cure remains challenging due to the high recurrence rates, especially in D-TGCT. Systemic therapies targeting the CSF1-CSF1R axis have emerged as promising treatment options. CSF1R tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, pexidartinib, and vimseltinib, alongside anti-CSF1R antibodies like emactuzumab, cabiralizumab, and lacnotuzumab, have shown encouraging results in managing TGCT, particularly when surgery is not feasible or poses significant morbidity. Other potential therapies, including local treatments and anti-inflammatory drugs, are being explored for TGCT management. This review provides an overview of systemic treatment options for D-TGCT, highlighting emerging therapeutic modalities and their potential implications. Effective management is crucial due to TGCT’s significant morbidity despite its non-life-threatening nature, necessitating novel approaches to improve patient prognosis and quality of life.

29 December 2025 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
ADAna Dolcan
Ana Dolcan
DFDaniela A Ferraro
Daniela A Ferraro
GTGiovani Dei Tos
Giovani Dei Tos
CCChristophe Cisarovsky
Christophe Cisarovsky
LWLaureline Wetterwald
Laureline Wetterwald
ADAntonia Digklia
Antonia Digklia
Breast sarcomas (BS) are considerably less prevalent than breast carcinomas. Nevertheless, they are often aggressive, resulting in substantial morbidity and mortality. Despite advances and the introduction of targeted therapies, the treatment continues to rely on cytotoxic chemotherapy. Given their rarity, this review comprehensively examines recent developments in BS therapies and explores how novel treatments may be integrated into the current standard of care. It also highlights emerging trends in adjuvant treatment for localized disease and targeted therapies for specific histologic subtypes in metastatic cases. This review synthesizes recent developments in BS and integrates novel therapies into the existing treatment paradigm. It underscores the heterogeneity among BS subtypes and discusses emerging trends in adjuvant therapies and targeted agents. Current literature was reviewed by a systematic search using PubMed, focusing on high-impact clinical trials, guidelines and recent reviews published up to January 2025. Although there is a growing understanding of genomic abnormalities associated with specific sarcoma subtypes, this knowledge has yet to be fully applied to personalized treatment strategies. Future research should focus on integrating genomic insights, enhancing trial design to improve patient's outcome. Robust interdisciplinary collaboration - combined with real-world data collection - is critical in improving treatment outcomes.

25 March 2026 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LWLaureline Wetterwald
Laureline Wetterwald
AKAnna Köck
Anna Köck
TWTania Wyss
Tania Wyss
SASilvia Arroz-Madeira
Silvia Arroz-Madeira
BPBorja Prat-Luri
Borja Prat-Luri
TPTatiana V. Petrova
Tatiana V. Petrova
Vertebrates rely on a network of blood vessels to meet organ demands for oxygen and nutrients. While endothelial cells are known to transport excess nutrients to white adipose tissue (WAT) for energy storage, how their metabolic state impacts this process remains unclear. Here, we identify MYCT1 as a conserved, pan-endothelial protein essential for WAT expansion. Endothelial-specific MYCT1 deletion limited WAT expansion independently of angiogenesis, adipogenesis, or systemic metabolic parameters. Mechanistically, MYCT1 interacted with the transmembrane endolysosomal proteins IFITM2/3 to restrict nutrient consumption by the vascular barrier. Loss of MYCT1 caused IFITM2/3 accumulation in early endosomes, promoting excessive endolysosomal degradation and mTORC1 hyperactivation, limiting the WAT energy storage capacity. Notably, endothelial-specific mTORC1 activation through TSC1 deletion phenocopied the fat storage defects of MYCT1 deficiency. Our findings establish the MYCT1–IFITM2/3 complex as endothelial metabolic checkpoint regulating systemic energy storage. Targeting MYCT1–IFITM2/3 may offer new therapeutic options for obesity and metabolic disorders.